Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.